LIGHT Proteins, Antibodies, cDNA Clones Research Reagents

TNFSF14 (TNF Superfamily Member 14) is a protein coding gene located on human chromosome 19p13.3. TNFSF14 is also known as LTg, CD258, HVEML and LIGHT. The human TNFSF14 gene encodes a 26350 Da protein containing 240 amino acids. The TNFSF14 protein is broadly expressed in liver, appendix and other tissues. Among its related pathways are PEDF Induced Signaling and LT-BetaR Pathway. TNFSF14 is related to signaling receptor binding and tumor necrosis factor receptor binding. FASLG is an important paralog of TNFSF14 gene. TNFSF14 is associated with some diseases, including Herpes Simplex and Cone-Rod Dystrophy 2.

LIGHT Protein (7)

    LIGHT Antibody (1)

      LIGHT cDNA Clone (53)


      LIGHT Lysate (6)

        More Product Popular With Customers

        LIGHT Background

        LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin β receptor (LTβR), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble non-signaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+ and CD8+ T cells. In addition, TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.

        LIGHT References

        • Ogawa T, et al. (2010) CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 183(3): 1206-12.
        • Kanodia S, et al. (2010) Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res. 70(10): 3955-64.
        • Hosokawa Y, et al. (2010) TNFSF14 coordinately enhances CXCL10 and CXCL11 productions from IFN-gamma-stimulated human gingival fibroblasts. Mol Immunol. 47(4): 666-70.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.